The blood samples used were from sixty-eight participants between the ages of fifty and seventy-five who had been diagnosed with AD and compared to a control group of two hundred and forty participants who were not diagnosed.
And now, the researchers hope to bring this protein misfolding early identification method to mainstream AD screenings and subsequent treatments via a new start-up known as betaSENSE.
“We plan to use the misfolding test to establish a screening method for older people and determine their risk of developing Alzheimer’s dementia,” Gerwert explained.
“The vision of our newly founded start-up betaSENSE is that the disease can be stopped in a symptom-free stage before irreversible damage occurs.”
Since its discovery, the immuno-infrared sensor has been patented worldwide. And following its approval as a diagnostic device, the team plans to bring it to market as soon as possible.
To read the study’s complete findings published in Alzheimer’s & Dementia, visit the link here.
If true crime defines your free time, this is for you: join Chip Chick’s True Crime Tribe.